【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於老年人 (除非用於思覺失調、雙極症、或化療止吐)。

思覺失調症、雙極症、重鬱症
Treatment of schizophrenia, bipolar mania and bipolar depression

Quetiapine fumarate is a dibenzothiazepine atypical antipsychotic. It is an antagonist at multiple neurotransmitter receptors in the brain: serotonin 5HT1A and 5HT2, dopamine D1 and D2, histamine H1 and adrenergic α-1 andα-2 receptors.

Absorption:
Bioavailability: 100%
Distribution:
Plasma protein binding: 83%
Metabolism:
Metabolized in liver via CYP3A4 to form two inactive metabolites
Excretion:
1. urine (73% as metabolites, <1% as unchanged drug)
2. feces (20%)
Elimination half-life:
6 hours

hypersensitivity to quetiapine fumarate or any component of the product

C

not recommended

Weight gain, headache, dizziness, somnolence, postural hypotension, xerostomia, dyspepsia, and constipation

Schizophrenia:
1. Initial 25 mg PO BID, may increase dosage to a target dose of 300-400 mg daily by the 4th day, given in 2-3 divided doses
2. Usual effective dosage range is 150-700 mg/day ( in 2-3 divided doses)
3. MAX dosage 800 mg/day
Bipolar mania:
1. Initial 50 mg PO BID on day 1, may increase dosage to 200 mg PO BID on day 4
2. Usual effective dosage range is 400-800 mg/day (in 2-3 divided doses)
3. MAX dosage 800 mg/day
Bipolar depression:
50 mg PO QD on day 1, then 100 mg on day 2, 200 mg on day 3, 300 mg on day 4 (all doses given at bedtime), patients requiring higher doses should receive 400 mg on day 5, increased to 600 mg on day 8